Free Trial
NASDAQ:LYRA

Lyra Therapeutics Q4 2024 Earnings Report

Lyra Therapeutics logo
$0.11 0.00 (-2.87%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$0.11 +0.00 (+3.42%)
As of 05/2/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lyra Therapeutics EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.04
One Year Ago EPS
-$1.26

Lyra Therapeutics Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.21 million
Beat/Miss
Beat by +$3.00 thousand
YoY Revenue Growth
N/A

Lyra Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
4:00PM ET

Lyra Therapeutics Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Lyra Therapeutics (LYRA) Gets a Hold from William Blair
Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c)
See More Lyra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyra Therapeutics and other key companies, straight to your email.

About Lyra Therapeutics

Lyra Therapeutics (NASDAQ:LYRA), a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

View Lyra Therapeutics Profile

More Earnings Resources from MarketBeat